Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Related Citations for PubMed (Select 22847744)

1.

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.

Konieczkowski DJ, Garraway LA.

Cell Res. 2013 Jan;23(1):13-4. doi: 10.1038/cr.2012.115. Epub 2012 Jul 31.

2.

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B.

Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.

3.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.

Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

4.

Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.

Yu S, Xiao X, Lu J, Qian X, Liu B, Feng J.

PLoS One. 2013 Jul 9;8(7):e68022. doi: 10.1371/journal.pone.0068022. Print 2013.

5.

[Some problems facing the molecular targeting therapy for colorectal cancer].

Xu JM.

Zhonghua Zhong Liu Za Zhi. 2009 May;31(5):321-3. Review. Chinese. No abstract available.

PMID:
19799077
6.

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].

Nozawa K, Watanabe T.

Gan To Kagaku Ryoho. 2010 May;37(5):791-4. Japanese.

PMID:
20495308
7.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
8.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.

Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1.

9.

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

de Reyniès A, Boige V, Milano G, Faivre J, Laurent-Puig P.

J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186. No abstract available.

10.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.

11.

[Molecular targeted therapy in colorectal cancer and its resistance].

Shitara K, Muro K.

Gan To Kagaku Ryoho. 2009 Apr;36(4):557-66. Japanese.

PMID:
19381027
12.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

13.

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L.

Cancer Chemother Pharmacol. 2013 Aug;72(2):397-403. doi: 10.1007/s00280-013-2211-0. Epub 2013 Jun 14.

PMID:
23765179
14.

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.

Clin Colorectal Cancer. 2011 Dec;10(4):325-32. doi: 10.1016/j.clcc.2011.03.028. Epub 2011 May 11.

PMID:
21729677
15.
16.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

17.

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.

Meriggi F, Di Biasi B, Abeni C, Zaniboni A.

Curr Drug Targets. 2009 Oct;10(10):1033-40. Review.

PMID:
19663767
18.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

19.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
20.

EGFR antibodies in colorectal cancer: where do they belong?

Grothey A.

J Clin Oncol. 2010 Nov 1;28(31):4668-70. doi: 10.1200/JCO.2010.29.3407. Epub 2010 Oct 4. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk